The Real-World Evidence Market Report is Segmented by Component (Services and Data Sets), Therapeutic Area (Oncology, Cardiology, Diabetes, Neurology, Psychiatry, and Other Therapeutics Areas), Application (Drug Development and Approvals, Medical Device Development and Approvals, Pharmacovigilance Studies, and Regulatory Decision-Making and Reimbursement/Coverage), End User (Pharmaceutical and Medical Device Companies, Clinical Research Organization, and Healthcare Providers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

According to newly released Global Real World Evidence Solutions market analysis report by Future Market Insights, the market was valued at US$ 39.2 Billion in 2021 and is expected to rise at a CAGR of 10% from 2022 to 2032. While comparing to its historical CAGR of only 8.6%, the market is predicted to rise significantly. During the projected period, the market is expected to create an absolute dollar opportunity of US$ 67.2 Billion. Owing to the support from regulatory bodies and increased R&D expenditure by global competitors, the global market for Real World Evidence Solutions is likely to be valued at US$ 110 Billion by the end of 2032.

Real World Evidence Solutions Market Report Scope

Real-world Data (RWD) Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], End User (Pharma, Payers, Providers) - Global Forecast to 2029

The global real world evidence solutions market was valued at USD 1.21 billion in 2021 and is expected to grow at a CAGR of 14.3% during the forecast period.

The real-world evidence (RWE) solutions market is expected to expand at a CAGR of ~10% during the forecast period. Key factors driving this growth include increasing regulatory support for RWE adoption, the rising incidence of chronic diseases, increased investment from pharmaceutical companies, the growing focus on personalized medicine and targeted therapies, the widespread adoption of […]

The size and share of the market is categorized based on Type (Clinical Setting Data, Claims Data, Pharmacy Data, Patient Powered Data) and Application (Pharmaceutical and Medical Device Companies, Healthcare Payers, Healthcare Providers, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Global Real World Evidence Solutions market size 2025 was XX Million. Real World Evidence Solutions Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Snapshot img

Real-World Evidence Solutions Market Analysis Report 2020-2024:

The real-world evidence solutions market size has the potential to grow by USD 697.92 mn during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by market landscape (oncology, immunology, cardiology, neurology, and others) and geography (Americas, EMEA, and APAC). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Clinigen Group Plc, ICON Plc, International Business Machines Corp., IQVIA Inc., Laboratory Corp. of America Holdings, Parexel International Corp., PerkinElmer Inc., Pharmaceutical Product Development LLC, SAS Institute Inc., and and Syneos Health Inc.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Real-World Evidence Solutions Market

Request a FREE sample now!

Market Competitive Analysis

The market is fragmented. Clinigen Group Plc, ICON Plc, International Business Machines Corp., IQVIA Inc., Laboratory Corp. of America Holdings, Parexel International Corp., PerkinElmer Inc., Pharmaceutical Product Development LLC, SAS Institute Inc., and and Syneos Health Inc. are some of the major market participants. Factors such as benefits of real-world evidence solutions will offer immense growth opportunities. To make the most of the opportunities, vendors should focus on growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this real-world evidence solutions market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this real-world evidence solutions market analysis report provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

Clinigen Group Plc
ICON Plc
International Business Machines Corp.
IQVIA Inc.
Laboratory Corp. of America Holdings
Parexel International Corp.
PerkinElmer Inc.
Pharmaceutical Product Development LLC
SAS Institute Inc.
and Syneos Health Inc.

Real-World Evidence Solutions Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

The report offers an up-to-date analysis regarding the current Global market scenario, latest trends and drivers, and the overall market environment. Americas will offer several growth opportunities to market vendors during the forecast period. The integration of ehrs with electronic data collection systems will significantly influence real-world evidence solutions market's growth in this region.

52% of the market’s growth will originate from Americas during the forecast period. The US is the key market for real-world evidence solutions market in Americas. This report provides an accurate prediction of the contribution of all segments to the growth of the real-world evidence solutions market size.

Real-World Evidence Solutions Market: Key Highlights of the Report for 2020-2024

CAGR of the market during the forecast period 2020-2024
Detailed information on factors that will real-world evidence solutions market growth during the next five years
Precise estimation of the real-world evidence solutions market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the real-world evidence solutions industry across Americas, EMEA, and APAC
A thorough analysis of the market’s competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of real-world evidence solutions market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

    Real-World Evidence Solutions Market Scope




    Report Coverage


    Details




    Page number


    120




    Base year


    2019




    Forecast period


    2020-2024




    Growth momentum & CAGR


    Accelerate at a CAGR of 13%




    Market growth 2020-2024


    USD 697.92 million




    Market structure


    Fragmented




    YoY growth (%)


    10.53




    Regional analysis


    Americas, EMEA, and APAC




    Performing market contribution


    Americas at

The clinical trial services market is estimated to be worth $9 billion in 2050 and is expected to grow at CAGR of over 14.1% during the forecast period.

The Real World Evidence Solutions Market size was valued at USD 15.52 USD billion in 2023 and is projected to reach USD 34.96 USD billion by 2032, exhibiting a CAGR of 12.3 % during the forecast period. Real World Evidence (RWE) Solutions use data collected in real-world, natural environments to produce insights for making decisions in healthcare. This data is extracted from electronic health records (EHRs), insurance claims, patient registries, and mobile health devices. RWE sources can be categorized into three categories that include observational research, pragmatic trials, and retrospective investigations. Some of the most prominent advantages of RWE include effective data acquisition, complex analysis, and real-time information. It is widely applicable in many fields, including drug and disease development, post-market safety and efficacy monitoring, health economics and outcomes research. The advantages of RWE Solutions are thus profound; they incorporate a substantial understanding of treatment return in various patients, improving clinicians’ choices, and abetting access to formalities. Recent developments include: In 2022, IQVIA acquired Health Data Research UK (HDR UK), a leading provider of RWE in the UK. In 2021, IBM acquired Envigo, a provider of RWE from animal models. In 2020, Cognizant acquired Healthagen, a provider of RWE from electronic health records.. Key drivers for this market are: Increasing Prevalence of Chronic Diseases and Introduction of Innovative Devices to Drive the Demand for C-arms . Potential restraints include: Lack of Presence of Standardized Regulations to Impede Market Growth Prospects. Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

Real World Evidence Solutions Market size was valued at USD 2.26 billion in 2019 and is poised to grow from USD 2.45 billion in 2023 to USD 4.97 billion by 2031, growing at a CAGR of 8.2% in the forecast period (2024-2031).

Прогнозируется, что в среднем 9,2% в период с 2023 по 2030 год, рынок мировой реальной мировой решений будет расширяться с оценки 2022 года в размере 2,49 млрд долларов. Размер рынка, рост, доля

Genomic Data Set for Real World Evidence (RWE) Applications market is size was valued at USD 1,704.60 Million by 2032 and CAGR 15.2% Market by Indications by Distribution Channels.

The global Real World Evidence (RWE) Solutions for Oncology market is projected to reach a value of 1018 million by 2033, exhibiting a CAGR of 12.8% during the forecast period of 2023-2033. Factors driving the market's growth include the increasing adoption of RWE in clinical trials, the growing need for personalized medicine, and the increasing availability of electronic health records (EHRs). The market is segmented by application (breast cancer, lung cancer, prostate cancer, others) and type (EHR, integrated dataset, others). North America is the largest regional market, followed by Europe and Asia Pacific. Key market trends include the increasing use of RWE in regulatory decision-making, the development of new data sources, and the growing emphasis on patient-centered outcomes. The market is highly competitive, with a number of established players and emerging startups. Some of the key companies operating in the market include Anthem, IMS Health, ICON Plc, Thermo Fisher Scientific, and Clinigen.

Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029

The Pharmaceutical Real-World Evidence (RWE) market is a dynamic and rapidly evolving sector that leverages real-world data to enhance decision-making across the healthcare landscape. By analyzing data from multiple sources, including electronic health records, insurance claims, and patient-reported outcomes, RWE pr

The U.S. Contract Research Organization (CRO) Services Market size was valued at USD 32.99 USD Billion in 2023 and is projected to reach USD 70.68 USD Billion by 2032, exhibiting a CAGR of 11.5 % during the forecast period. The U.S. Contract Research Organization (CRO) market includes organizations offering issued contracts for research services to pharmaceutical, biotechnology, and medical device companies. These renderings cover broadly clinical trials, regulatory affairs, data management, biostatistics, and pharmacovigilance. CROs are fully utilized by pharmaceutical companies to enhance drug development procedures, curb costs, and shorten the drug market entry period. Ranges cover early-stage phase clinical trials and post-marketing surveillance. Key trends in the market comprise the introduction of CRO services which are specialized, growing virtual trials and decentralized clinical trials, and the use of AI and real-world evidence in clinical research is the fourth trend. US CRO services are a vital part of evolving and globalizing the pharmaceutical industry, which allows drug development endeavors to achieve success and operate efficiently. Key drivers for this market are: Rising Prevalence of Poultry Diseases is Anticipated to Drive the Market Growth. Potential restraints include: Limited Availability of Experienced Workforce is Expected to Restrict Market Growth. Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

According to Cognitive Market Research, the global Electronic Clinical Outcome Assessment (eCOA) Solutions Market size is USD 6.5 billion in 2024 and will expand at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031. Market Dynamics of Electronic Clinical Outcome Assessment (eCOA) Solutions Market

Key Drivers for Electronic Clinical Outcome Assessment (eCOA) Solutions Market

Growing emphasis on patient-centric healthcare models drives demand for electronic clinical outcome assessment (eCOA) solutions - Growing emphasis on patient-centric healthcare models drives demand for electronic clinical outcome assessment (eCOA) solutions. With a shift towards patient-centric care, healthcare providers and researchers prioritize accurate, real-time patient feedback. eCOA solutions facilitate this by streamlining data collection and analysis, improving patient engagement, and ensuring higher data quality. These solutions enable timely adjustments in treatment plans based on patient-reported outcomes, ultimately enhancing the overall effectiveness of clinical trials and patient care. This trend is bolstered by regulatory support and the increasing need for comprehensive patient data in personalized medicine.
Increasing adoption of cloud-based and web-hosted deployment models enhances accessibility and efficiency of eCOA systems.

Key Restraints for Electronic Clinical Outcome Assessment (eCOA) Solutions Market

High initial costs and maintenance expenses limit the widespread adoption of eCOA solutions in smaller organizations.
Data privacy and security concerns hinder the deployment of eCOA solutions in highly regulated healthcare environments.

Introduction of the Electronic Clinical Outcome Assessment (eCOA) Solutions Market

Electronic Clinical Outcome Assessment (eCOA) solutions encompass software, services, and devices used to collect patient, clinician, and observer-reported outcomes digitally. eCOA enhances data accuracy, reduces errors, and streamlines the clinical trial process by leveraging electronic patient-reported outcomes (ePRO), clinician-reported outcomes (eCLINRO), observer-reported outcomes (eOBSRO), and performance-reported outcomes (ePERFO). The market for eCOA solutions is experiencing robust growth driven by increasing adoption in clinical trials, the rising prevalence of chronic diseases, and the need for real-world evidence generation. Technological advancements, including the integration of wearables and mobile devices, further propel market expansion.

Market Analysis for Synthetic Data Solution The global synthetic data solution market is projected to reach USD XXX million by 2033, growing at a CAGR of XX% from 2025 to 2033. The increasing demand for synthetic data in various industries, such as financial services, retail, and healthcare, drives this growth. Synthetic data offers a privacy-preserving alternative to real-world data, enabling organizations to train and evaluate models without compromising sensitive information. The growing adoption of cloud-based solutions and the increasing need for data privacy and security further contribute to market growth. Market segments include deployment types (cloud-based and on-premises) and applications (financial services industry, retail industry, medical industry, and others). Key regional markets include North America, South America, Europe, Middle East & Africa, and Asia Pacific. Major companies operating in the market include LightWheel AI, Hanyi Innovation Technology, Haohan Data Technology, Haitian Ruisheng Science Technology, and Baidu. Trends such as the adoption of artificial intelligence (AI) and machine learning (ML) and the rising concern over data privacy and governance are expected to shape the market's future.

EHRs and EMRs: Electronic health records are essential for managing patient information, facilitating collaboration between providers, and improving patient outcomes.RCM software: RCM software helps healthcare providers manage billing, claims processing, and revenue collection, enhancing financial performance.Patient engagement tools: These tools enable patients to access their medical records, schedule appointments, and communicate with healthcare providers remotely. Recent developments include: September 2022:Sharecare unveiled Smart Omix, a patented digital clinical research solution that enables mobile research studies to collect real-world data and develop digital biomarkers. The features of Smart Omix are critical in expanding clinical research's relevance, equity, and data integrity throughout the healthcare continuum., May 2022:Modmed introduced an OBGYN-specific software suite. Obstetrics and gynecology will see practice and workflow innovation thanks to ModMed OBGYN, an all-in-one EHR, practice management, patient engagement, payments, image and inventory management, and analytics solutions.. Notable trends are: Increase in the geriatric population worldwide to propel market growth.